Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Utility of serum CA 19-9 monitoring in preoperative radiotherapy for pancreatic cancer
Autore:
Ohara, K; Tatsuzaki, H; Molotkova, NG; Oda, T; Yuzawa, K; Saida, Y; Matsuzaki, Y; Shimizu, W; Todoroki, T; Fukao, K; Tanaka, N; Itai, Y;
Indirizzi:
Univ Tsukuba, Inst Clin Med, Dept Radiol, Tsukuba, Ibaraki 3058575, Japan Univ Tsukuba Tsukuba Ibaraki Japan 3058575 sukuba, Ibaraki 3058575, Japan Univ Tsukuba, Inst Clin Med, Dept Surg, Tsukuba, Ibaraki 3058575, Japan Univ Tsukuba Tsukuba Ibaraki Japan 3058575 sukuba, Ibaraki 3058575, Japan Univ Tsukuba, Inst Clin Med, Dept Gastroenterol, Tsukuba, Ibaraki 3058575,Japan Univ Tsukuba Tsukuba Ibaraki Japan 3058575 Tsukuba, Ibaraki 3058575,Japan
Titolo Testata:
HEPATO-GASTROENTEROLOGY
fascicolo: 39, volume: 48, anno: 2001,
pagine: 859 - 863
SICI:
0172-6390(200105/06)48:39<859:UOSC1M>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
INTRAOPERATIVE RADIATION-THERAPY; CA-19-9 LEVELS; CURATIVE RESECTION; PROGNOSTIC VALUE; ADENOCARCINOMA; CARCINOMA; CHEMORADIATION; IRRADIATION; TRIAL; PANCREATICODUODENECTOMY;
Keywords:
tumor control; tumor response; metastasis prediction;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Ohara, K Univ Tsukuba, Inst Clin Med, Dept Radiol, 1-1-1 Tennodai, Tsukuba, Ibaraki3058575, Japan Univ Tsukuba 1-1-1 Tennodai Tsukuba Ibaraki Japan 3058575 , Japan
Citazione:
K. Ohara et al., "Utility of serum CA 19-9 monitoring in preoperative radiotherapy for pancreatic cancer", HEP-GASTRO, 48(39), 2001, pp. 859-863

Abstract

Background/Aims: Pancreatic cancer is extremely refractory even to aggressive treatments including surgery, resulting in early metastasis and/or local recurrence. We investigated changes in serum tumor marker CA 19-9 levels during preoperative radiotherapy in conjunction with initial treatment failure. Methodology: Twenty-three patients presenting with localized disease and an increased serum CA 19-9 level, who were slated to undergo pancreatectomy and/or intraoperative radiotherapy following preoperative radiotherapy werereviewed. CA 19-9 response, the ratio of post-radiotherapy level before laparotomy to pre-radiotherapy level, was analyzed in relation to disease-control time and survival. Results: Eleven patients revealed metastasis at restaging or laparotomy; 12 patients (52%) completed aggressive treatments. Initial failure was identified at the liver (52%), peritoneum (52%), or local site (26%) with a median disease-control time of 91 days; 7 patients showed combined failure. Allbut 1 patient died of cancer with a median survival time of 264 days. CA 19-9 response (range: 0-1185%) did not correlate with disease-control time or survival; 8 progressive-disease patients (> 140% response), however, showed significantly shorter disease-control time than 15 nonprogressive-disease patients (less than or equal to 140% response). Conclusions: CA 19-9 monitoring is useful in preoperative radiotherapy foridentifying patients who will not benefit by succeeding aggressive treatments by predicting early metastasis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 07:49:10